Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Territorial-based management of patients with cancer on active treatment following the Piacenza (north Italy) Model. Results of 4 consecutive years.].
Cavanna L, Citterio C, Di Nunzio C, Zaffignani E, Cremona G, Vecchia S, De Ponzio M, Riva A, Proietto M, Mordenti P, Bosi C, Vallisa D, Andena AM, Zanlari L, Palermo E, Iofrida M, Groppi L, Civardi G, Artioli F. Cavanna L, et al. Among authors: bosi c. Recenti Prog Med. 2021 Dec;112(12):785-791. doi: 10.1701/3710.37001. Recenti Prog Med. 2021. PMID: 34924573 Italian.
[A Morgagni-Larrey hernia. A case report].
Mariani G, Bakara C, Bosi C, Monaco R, Andreoli M, Mariani MC. Mariani G, et al. Among authors: bosi c. Minerva Chir. 1992 Jan;47(1-2):69-72. Minerva Chir. 1992. PMID: 1553057 Review. Italian.
Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
Bassi S, Stroppa EM, Moroni CF, Arbasi MC, Trabacchi E, Di Franco A, Lazzaro A, Bernuzzi P, Moretto M, Arcari A, Bosi C, Riva A, Cavanna L, Vallisa D. Bassi S, et al. Among authors: bosi c. Blood Transfus. 2015 Jul;13(3):478-83. doi: 10.2450/2015.0198-14. Epub 2015 Feb 2. Blood Transfus. 2015. PMID: 25761321 Free PMC article.
Re: The first report on coronavirus disease 2019 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey: Consideration of recent findings on COVID-19 vaccine adherence in cancer patients.
Cavanna L, Citterio C, Cattadori E, Bosi C, Caprioli S. Cavanna L, et al. Among authors: bosi c. Eur J Cancer. 2021 Nov;158:251-252. doi: 10.1016/j.ejca.2021.07.048. Epub 2021 Sep 25. Eur J Cancer. 2021. PMID: 34649763 Free PMC article. No abstract available.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, Palumbo GA. Palandri F, et al. Among authors: bosi c. Cancer. 2021 Aug 1;127(15):2657-2665. doi: 10.1002/cncr.33541. Epub 2021 Apr 1. Cancer. 2021. PMID: 33794557 Free article.
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M. Palandri F, et al. Among authors: bosi c. Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1. Blood Cancer J. 2021. PMID: 33414394 Free PMC article. No abstract available.
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M. Palandri F, et al. Among authors: bosi c. Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108288 Free PMC article.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F. Polverelli N, et al. Among authors: bosi c. Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. Online ahead of print. Hematol Oncol. 2018. PMID: 29624703
107 results